☆ 4.8 Letter

The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice

GASTROENTEROLOGY (2010)

Journal

GASTROENTEROLOGY

Volume 138, Issue 2, Pages 789-791

Publisher

W B SAUNDERS CO-ELSEVIER INC

DOI: 10.1053/j.gastro.2009.09.077

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Gastroenterology & Hepatology

Utilization of Dietitians in the Management of Irritable Bowel Syndrome by Members of the American College of Gastroenterology

Kate Scarlata, Shanti Eswaran, Jason R. Baker, William D. Chey

Summary: The aim of this study was to identify the benefits and barriers of using a gastroenterology (GI) dietitian for irritable bowel syndrome (IBS) care. The results of the survey showed gaps in nutrition-based interventions for IBS care, as well as a significant number of respondents lacking access to a local GI dietitian, despite the majority agreeing that it would be beneficial.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation

Lin Chang, William D. Chey, Aamer Imdad, Christopher V. Almario, Adil E. Bharucha, Susan Diem, Katarina B. Greer, Brian Hanson, Lucinda A. Harris, Cynthia Ko, M. Hassan Murad, Amit Patel, Eric D. Shah, Anthony J. Lembo, Shahnaz Sultan

Summary: This article provides evidence-based practice recommendations for the pharmacological treatment of chronic idiopathic constipation (CIC), with 10 recommendations agreed upon by a multidisciplinary guideline panel. Some medications, such as polyethylene glycol and linaclotide, are strongly recommended for CIC treatment in adults, while others, such as fiber, are conditionally recommended.

GASTROENTEROLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation

Lin Chang, William D. Chey, Aamer Imdad, Christopher V. Almario, Adil E. Bharucha, Susan Diem, Katarina B. Greer, Brian Hanson, Lucinda A. Harris, Cynthia Ko, M. Hassan Murad, Amit Patel, Eric D. Shah, Anthony J. Lembo, Shahnaz Sultan

Summary: This article is a clinical practice guideline for the pharmacological treatment of chronic idiopathic constipation (CIC) in adults. It provides evidence-based practice recommendations, including the use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide, and prucalopride. The article also highlights limitations and gaps in the evidence to guide future research opportunities and improve patient care.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford

Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.

GASTROENTEROLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Dipesh H. Vasant, Peter A. Paine, Christopher J. Black, Lesley A. Houghton, Hazel A. Everitt, Maura Corsetti, Anurag Agrawal, Imran Aziz, Adam D. Farmer, Maria P. Eugenicos, Rona Moss-Morris, Yan Yiannakou, Alexander C. Ford

Summary: This guideline aims to review and summarize current evidence on irritable bowel syndrome (IBS) to inform clinical practice and provide guidance, with specific treatment recommendations based on evidence from a comprehensive search of medical literature. The guideline highlights the efficacy of dietary, pharmacological, and psychological therapies in treating IBS, and provides specific recommendations according to the Grading of Recommendations Assessment, Development, and Evaluation system.

GUT (2021)

Add to Collection

Review Pharmacology & Pharmacy

An Overview of Systematic Reviews of Herbal Medicine for Irritable Bowel Syndrome

Hyejin Jun, Seok-Jae Ko, Keumji Kim, Jinsung Kim, Jae-Woo Park

Summary: This study assessed the methodology and quality of evidence of systematic reviews (SRs) on the use of herbal medicines (HMs) for irritable bowel syndrome (IBS). The findings suggest that HM can be considered as an effective and safe treatment for IBS. However, the methodological quality of the included SRs and the quality of evidence were generally low. Well-designed randomized controlled trials are needed to better evaluate the safety and efficacy of HM in IBS treatment.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Post COVID-19 irritable bowel syndrome

Giovanni Marasco, Cesare Cremon, Maria Raffaella Barbaro, Giulia Cacciari, Francesca Falangone, Anna Kagramanova, Dmitry Bordin, Vasile Drug, Egidia Miftode, Pietro Fusaroli, Salem Youssef Mohamed, Chiara Ricci, Massimo Bellini, Mohammed Masudur Rahman, Luigi Melcarne, Javier Santos, Beatriz Lobo, Serhat Bor, Suna Yapali, Deniz Akyol, Ferdane Pirincci Sapmaz, Yonca Yilmaz Urun, Tugce Eskazan, Altay Celebi, Huseyin Kacmaz, Berat Ebik, Hatice Cilem Binicier, Mehmet Sait Bugdayci, Munkhtsetseg Banzragch Yagci, Husnu Pullukcu, Berrin Yalinbas Kaya, Ali Tureyen, Ibrahim Hatemi, Elif Sitre Koc, Goktug Sirin, Ali Riza Caliskan, Goksel Bengi, Esra Ergun Alis, Snezana Lukic, Meri Trajkovska, Keren Hod, Dan Dumitrascu, Antonello Pietrangelo, Elena Corradini, Magnus Simren, Jessica Sjoelund, Navkiran Tornkvist, Uday C. Ghoshal, Olga Kolokolnikova, Antonio Colecchia, Jordi Serra, Giovanni Maconi, Roberto De Giorgio, Silvio Danese, Piero Portincasa, Antonio Di Sabatino, Marcello Maggio, Elena Philippou, Yeong Yeh Lee, Daniele Salvi, Alessandro Venturi, Claudio Borghi, Marco Zoli, Paolo Gionchetti, Pierluigi Viale, Vincenzo Stanghellini, Giovanni Barbara

Summary: This study aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction among hospitalized patients with SARS-CoV-2 infection. The results showed that patients with COVID-19 had higher rates of gastrointestinal symptoms on hospital admission and lower rates of constipation and hard stools at 12 months post-infection compared to the control group. Additionally, the rate of irritable bowel syndrome was significantly higher in patients with COVID-19 than in controls.

GUT (2023)

Add to Collection

Review Medicine, General & Internal

Meditation and Irritable Bowel Syndrome, a Systematic Review and Meta-Analysis

Cristian-Ioan Babos, Daniel-Corneliu Leucuta, Dan Lucian Dumitrascu

Summary: This study assessed the effectiveness of meditation/mindfulness in improving symptoms severity, quality of life, and other associated mental conditions in patients with irritable bowel syndrome (IBS). The meta-analysis results showed statistically significant improvements in symptom score, quality of life, spiritual scale, and pain score in the mindfulness group compared to the control group.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Biochemical Research Methods

Subtyping irritable bowel syndrome using cluster analysis: a systematic review

Diana Zarei, Amene Saghazadeh, Nima Rezaei

Summary: This literature review examines the use of cluster analysis in irritable bowel syndrome (IBS) patients. It reveals that IBS can be classified into different subgroups based on various factors. However, the number of clusters varies across studies due to methodological heterogeneity. The research further explores the clinical symptoms, rectal perception, immunological findings, and microbial composition of IBS.

BMC BIOINFORMATICS (2023)

Add to Collection

Review Gastroenterology & Hepatology

Association between irritable bowel syndrome and micronutrients: A systematic review

Schin Bek, Yao Neng Teo, Xin-Hui Tan, Kristie H. R. Fan, Kewin Tien Ho Siah

Summary: Patients with irritable bowel syndrome (IBS) are at risk of developing micronutrient deficiencies, especially in vitamin B1, B2, calcium, iron, and zinc, due to exclusion diets. Dietary management of IBS patients should include a dietitian review to ensure nutritional adequacy.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Endometriosis and irritable bowel syndrome: A systematic review and meta-analyses

Michelle Y. Nabi, Samal Nauhria, Morgan Reel, Simon Londono, Anisha Vasireddi, Mina Elmiry, Prakash V. A. K. Ramdass

Summary: The study aimed to estimate the pooled odds ratio of endometriosis and irritable bowel syndrome, and the pooled prevalence of irritable bowel syndrome in patients with endometriosis. The results showed that patients with endometriosis have a threefold increased risk of developing irritable bowel syndrome, and the prevalence of irritable bowel syndrome in women with endometriosis was 23.4%.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome

Maria Rosa Ingrosso, Gianluca Ianiro, Judy Nee, Anthony J. Lembo, Paul Moayyedi, Christopher J. Black, Alexander C. Ford

Summary: This study aimed to evaluate the efficacy and safety of peppermint oil in the treatment of IBS. The results showed that peppermint oil was more effective than placebo, but adverse events occurred more frequently.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Review Gastroenterology & Hepatology

AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review

William D. Chey, Jana G. Hashash, Laura Manning, Lin Chang

Summary: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects quality of life. The latest clinical practice update recommends dietary modifications, such as the low-FODMAP diet, as the primary treatment for IBS symptoms. Best practice advice includes involving patients who are insightful and motivated in dietary changes, avoiding restrictive diets for patients who are poor candidates, highlighting the benefits of soluble fiber and the low-FODMAP diet, and following a three-phase approach for the low-FODMAP diet. The efficacy of a gluten-free diet for IBS is uncertain and there is limited evidence to support the routine use of biomarkers in clinical practice.

GASTROENTEROLOGY (2022)

Add to Collection

Review Medicine, General & Internal

The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review

Jaroslaw Daniluk, Ewa Malecka-Wojciesko, Barbara Skrzydlo-Radomanska, Grazyna Rydzewska

Summary: Mebeverine has shown significant efficacy in treating irritable bowel syndrome, particularly in reducing abdominal pain and improving related symptoms. It has a good safety profile with minimal adverse effects.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Irritable bowel syndrome: treatment based on pathophysiology and biomarkers

Michael Camilleri, Guy Boeckxstaens

Summary: This article evaluates the evidence that targeted pathophysiological mechanisms and customized treatments can be an alternative approach to treating patients with irritable bowel syndrome (IBS). The authors conducted a literature review on the mechanisms and treatments of IBS, identifying various noninvasive clinical tests that can assess the underlying mechanisms responsible for symptom generation. These mechanisms include rectal evacuation disorders, abnormal transit, visceral hypersensitivity or hypervigilance, bile acid diarrhea, sugar intolerances, barrier dysfunction, the microbiome, immune activation, and chemicals released by these mechanisms. The authors also recognized the basic molecular mechanisms contributing to these pathophysiologies, offering opportunities for interventions with medications targeted at specific food components, receptors, and potentially the microbiome. Although the evidence supporting interventions for each mechanism varies, the current state-of-the-art allows for a shift from symptom-based treatment to individualized treatment guided by pathophysiology and clinically identified biomarkers.

GUT (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Immortal time bias in a retrospective study examining colorectal cancer mortality according to adherence to colonoscopy

Conchubhair Winters, Alexander Charles Ford

GUT (2023)

Add to Collection

Article Gastroenterology & Hepatology

Diabetes mellitus is an independent risk factor for a greater frequency of early satiation and diarrhea at one and three years: Two prospective longitudinal population-based studies

Natasha A. Koloski, Michael Jones, Marjorie M. Walker, Michael Horowitz, Gerald Holtmann, Nicholas J. Talley

Summary: Diabetes is an independent risk factor for an increased frequency of gastrointestinal symptoms, adjusting for lifestyle and psychological factors.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis

Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford

Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis

Michelle Bosman, Fabienne Smeets, Sigrid Elsenbruch, Jan Tack, Magnus Simren, Nicholas Talley, Bjorn Winkens, Ad Masclee, Daniel Keszthelyi

Summary: This study conducted a systematic review and meta-analysis to investigate the placebo response in pharmacological trials for functional dyspepsia (FD). The study found that the pooled placebo response rate ranged from 35.5% to 39.6% depending on the responder definition used. Lower baseline symptom scores were significantly associated with higher placebo response rates. The study suggests considering entry criteria based on symptom severity and separate reporting of core FD symptoms in future trials.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Economic living standard and abdominal pain mediate the association between functional gastrointestinal disorders and depression or anxiety

M. H. Simon, P. E. Heenan, C. Frampton, S. Bayer, J. Keenan, de N. K. Boer, N. C. Roy, N. J. Talley, R. B. Gearry

Summary: This study examines the association between functional gastrointestinal disorders (FGIDs) and depression and anxiety, and identifies the covariates influencing this association. The study finds that economic standard of living, pain, and IBS phenotype are significant independent factors associated with depression and anxiety in FGID cases.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Willingness to pay for medications among patients with Rome IV irritable Bowel syndrome

Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

Summary: This study examined willingness to pay for medications among individuals with irritable bowel syndrome (IBS). The results showed that women and individuals with an annual income of 30,000 pounds or more were more likely to be willing to pay for medication. In addition, individuals with lower IBS-related quality of life were more willing to pay for a medication that could improve their symptoms.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford

Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome

Vivek C. C. Goodoory, Elspeth A. A. Guthrie, Cho E. E. Ng, Christopher J. J. Black, Alexander C. C. Ford

Summary: Irritable bowel syndrome (IBS) has a substantial impact on the quality of life of affected individuals, and the negative impact is worse than observed in some severe chronic organic conditions.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Review Gastroenterology & Hepatology

Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis

Maria Rosa Ingrosso, Michael Camilleri, Jan Tack, Gianluca Ianiro, Christopher J. Black, Alexander C. Ford

Summary: This study evaluated the efficacy and safety of drugs for gastroparesis through a network meta-analysis. The results showed that oral dopamine antagonists and tachykinin-1 antagonists were more effective than placebo. For individual symptoms, oral metoclopramide showed good efficacy for nausea, fullness, and bloating. However, the confidence in the evidence for most comparisons was low to moderate, indicating a need for more effective therapies for gastroparesis.

GASTROENTEROLOGY (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection

Lucas Wauters, Paul R. Harris, Marjorie M. Walker, Carolina A. Serrano, Andrea Villagran, Gurpreet S. Rakhra, Jean E. Crabtree, Nicholas J. Talley

Summary: This article is connected to the paper by Broeders et al. To access this article, visit the provided link.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Substantial Variability in Placebo and Nocebo Responses Challenges the Validity of Network Meta-Analysis of Gastroparesis Pharmacotherapy Reply

Maria rosa Ingrosso, Christopher j. Black, Alexander c. Ford

GASTROENTEROLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review

Brandon Stretton, Joshua Kovoor, Stephen Bacchi, Shantel Chang, Benjamin Ngoi, Tess Murray, Thomas C. Bristow, Jonathan Heng, Aashray Gupta, Christopher Ovenden, Guy Maddern, Campbell H. Thompson, Leonie Heilbronn, Mark Boyd, Christopher Rayner, Nicholas J. Talley, Michael Horowtiz

Summary: This review summarizes the direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes, focusing on their efficacy for inducing weight loss and improving metabolic health markers. Five studies which fulfilled the inclusion criteria were identified. Randomized trials support the superior efficacy of semaglutide over other GLP-1 RAs in terms of weight loss, but tirzepatide is more effective than semaglutide.

INTERNAL MEDICINE JOURNAL (2023)

Add to Collection

Article Gastroenterology & Hepatology

Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study

Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford

Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply

Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study

Christy Riggott, Keeley M. Fairbrass, Christian P. Selinger, David J. Gracie, Alexander C. Ford

Summary: The use of opioids in patients with inflammatory bowel disease (IBD) is associated with psychological comorbidity and an increased risk of intestinal resection, particularly with stronger formulations. Future studies should classify the risks of different opioids to develop reliable prescribing algorithms, and evaluate the effectiveness of addressing psychological factors as an opioid avoidance strategy in routine IBD care.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.